[
    [
        {
            "time": "",
            "original_text": "大参林：控股股东柯康保解除质押685万股",
            "features": {
                "keywords": [
                    "大参林",
                    "控股股东",
                    "柯康保",
                    "解除质押",
                    "685万股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "零售"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "大参林：控股股东柯康保解除质押685万股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "大参林(603233.SH)：控股股东、一致行动人之一柯康保解押685万股",
            "features": {
                "keywords": [
                    "大参林",
                    "603233.SH",
                    "控股股东",
                    "一致行动人",
                    "柯康保",
                    "解押",
                    "685万股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "零售"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "大参林(603233.SH)：控股股东、一致行动人之一柯康保解押685万股",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-05",
            "original_text": "2021年医药行业5月策略报告：短期波动不改长期趋势 仍重点推荐疫苗等",
            "features": {
                "keywords": [
                    "医药行业",
                    "5月策略报告",
                    "短期波动",
                    "长期趋势",
                    "疫苗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2021年医药行业5月策略报告：短期波动不改长期趋势 仍重点推荐疫苗等",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "【招商医药】连锁药店行业深度报告之二-基于4家药房上市公司全方位指标横向对比",
            "features": {
                "keywords": [
                    "招商医药",
                    "连锁药店",
                    "行业深度报告",
                    "药房上市公司",
                    "指标对比"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "零售"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【招商医药】连锁药店行业深度报告之二-基于4家药房上市公司全方位指标横向对比",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "艾力斯(688578)：核心产品伏美替尼正式商业化",
            "features": {
                "keywords": [
                    "艾力斯",
                    "688578",
                    "核心产品",
                    "伏美替尼",
                    "正式商业化"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "创新药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "艾力斯(688578)：核心产品伏美替尼正式商业化",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]